• Adventrx Pharmaceuticals Inc., of San Diego, said it reached an agreement with the FDA on a single pivotal trial for ANX-514 (docetaxel for injectable emulsion) in cancer. The 400-patient study will be a noninferiority design with a primary endpoint of comparing fluid retention following treatment with ANX-514 administered without corticosteroid premedication, vs. Taxotere (docetaxel) administered with corticosteroid premedication. ANX-514 is designed to improve the tolerability and safety of docetaxel and decrease toxicities.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter